A few nervous comments surfacing from the commentariat. I used...

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 129 Last

Share
Profile

Follow
bluey2015

73 Posts.

18

23/06/17

10:18

Post #: 25447503
Share

Originally posted by Southoz ↑

I would say you are one inch away from understanding my point Djwally.

Professor A is a legitimate scientist. The Leave-one out is a cross validation method is widely used in the development of prediction models. The aim of it is to try and control for the confirmation biases of model developers. But in and of itself it is not sufficient.

Even Wikipedia will tell you that people are pretty leery about exactly how much cross-validation techniques improve external validity. Hence newer methods - swap sampling - which I have never heard of – are attracting attention.

My argument is not which method is better – but rather there is a risk point that people aren’t seeing.

If prediction models were perfect with legitimate scientists and accepted cross validation methods the FDA wouldn’t require prospective studies. But they do ... for very good reasons.

And yes numbers in a sense you are exactly right. Matching is required. In other words a significant correlation to clinical diagnosis. This will get you approval. Further studies demonstrating sensitivity and specificity back to a reference standard often follow after this initial approval. Because it is only this that can demonstrate clinical utility / cost effectiveness which is necessary for commenrcial success.

As interesting as these discussions are unfortunately for me its back to the real world salt mine of research. Be interesting to see how what transpires here with RAP.

Expand

A few nervous comments surfacing from the commentariat.
I used to hate the presence of bots capping.
Now as I see them at work since 10:10 am, they give me re-assurance that the big boys are still in there.
Regards
Bluey

RAP Price at posting: 31.5¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

HotCopper Highlights: Your most watched stocks for Week 46, 2024

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

First 129 Last

Add RAP (ASX) to my watchlist

A few nervous comments surfacing from the commentariat. I used...

Top Stories

HotCopper Highlights: Your most watched stocks for Week 46, 2024

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Cyclone signs MOU with Vale for development of Iron Bear play

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Banshee's historic trenches prove rich in antimony and gold for GDM

Featured News